GLP-1 Side Effects by Medication: A Complete Drug-by-Drug Comparison
Medically Reviewed by
Board Certified Internal Medicine
Published
Mar 16, 2026
Last Reviewed
Mar 18, 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
GLP-1 Side Effects: What the Clinical Trials Show
The most common GLP-1 side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These occur in 20–44% of patients depending on the drug and dose, are most pronounced during dose escalation, and typically diminish over 4–12 weeks. Serious adverse events — including pancreatitis, gallbladder disease, and severe hypoglycemia — occur in less than 2% of patients in clinical trials. Understanding which side effects are most likely with your specific drug helps you prepare and reduces the chance of unnecessary discontinuation.
Semaglutide Side Effects (Ozempic & Wegovy)
In the STEP 1 trial (Wegovy 2.4mg), nausea was reported by 44% of patients, diarrhea by 30%, vomiting by 24%, and constipation by 24%. Approximately 7% of patients discontinued due to GI adverse events. Nausea peaks during the first 4–8 weeks and during each dose escalation step. Serious adverse events were uncommon: pancreatitis occurred in 0.3% of patients (vs 0.1% placebo) and gallbladder disease in 2.6% (vs 1.2% placebo). Heart rate increase of 1–4 bpm is consistently observed with semaglutide and is not considered clinically significant in the trials. At the higher Wegovy dose (2.4mg vs Ozempic's 2.0mg maximum), GI side effects are modestly more frequent.
Tirzepatide Side Effects (Mounjaro & Zepbound)
Tirzepatide's dual GIP/GLP-1 mechanism produces a different side effect signature. In the SURMOUNT-1 trial (Zepbound 15mg), nausea was reported by 31% of patients — lower than semaglutide despite achieving greater weight loss. Diarrhea occurred in 23%, vomiting in 20%, and constipation in 17%. Notably, tirzepatide produces more pronounced reductions in appetite and less severe nausea per unit of weight loss compared to semaglutide in head-to-head comparisons. The 10mg and 15mg doses show higher GI event rates than 5mg, consistent with dose-response patterns seen with semaglutide.
Liraglutide Side Effects (Saxenda)
Liraglutide (Saxenda 3.0mg daily) produces GI side effects similar in type to semaglutide but with some differences in frequency. As a daily injection vs weekly, liraglutide does not have a prolonged peak concentration, which some patients tolerate better. In the SCALE trial, nausea was reported in 39%, diarrhea in 21%, constipation in 19%, and vomiting in 16%. Discontinuation due to GI adverse events occurred in approximately 9% of patients — slightly higher than with weekly semaglutide. The daily injection schedule adds an additional tolerability burden that makes Saxenda less preferred when weekly alternatives are available.
Serious Adverse Events: What's the Real Risk?
Pancreatitis is the most discussed serious adverse event with GLP-1 drugs. Across large cardiovascular outcome trials (LEADER, SUSTAIN-6, SURPASS-CVOT), the incidence of acute pancreatitis with GLP-1 therapy was 0.1–0.3% — not statistically different from placebo in most trials. Gallbladder disease (cholelithiasis, cholecystitis) is more clearly associated, with approximately 0.5–1.5% excess risk over placebo. Diabetic retinopathy worsening was observed in SUSTAIN-6 (semaglutide) but has not been replicated in subsequent trials. The postulated mechanism is rapid glucose normalization causing transient retinal ischemia. Thyroid C-cell tumors remain a theoretical concern based on animal data; no confirmed human cases of GLP-1-induced MTC have been published.
Side Effect Timeline: When They Peak and Fade
GI side effects with all GLP-1 drugs follow a predictable pattern. Onset occurs within the first 1–3 days after each new dose or dose escalation. Peak intensity is typically in weeks 2–6 of any given dose level. For most patients, nausea substantially diminishes or resolves within 4–12 weeks of reaching a stable dose. The slow titration schedules built into every GLP-1 drug — starting at a fraction of the therapeutic dose and escalating over 16–20 weeks — exist specifically to minimize this early-phase side effect burden. Skipping dose escalation steps significantly increases GI adverse events.
Evidence-Based Strategies to Reduce Side Effects
Several strategies reduce GI side effects during GLP-1 therapy: eating small, low-fat meals slows the GI response to delayed gastric emptying; avoiding high-fat, greasy, or heavily spiced foods during the first months reduces nausea triggers; staying upright for 30–60 minutes after eating reduces reflux from delayed gastric emptying; ginger tea or ginger chews have modest evidence in chemotherapy-induced nausea and are reasonable to try for GLP-1 nausea; staying well hydrated prevents dehydration from vomiting or diarrhea episodes. If side effects are severe enough to affect daily function or nutritional intake, speak with your prescribing physician about slowing the titration schedule — this is explicitly supported in all drug labeling.
Frequently Asked Questions
These answers are for informational purposes only. Always consult your physician for personalized medical advice.
Was this article helpful?
Scientific References & Further Reading
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.
- FDA Drug Approvals Database — GLP-1 Receptor Agonists. U.S. Food & Drug Administration.
- PubMed — GLP-1 Receptor Agonist Research Index. National Library of Medicine.
- Mayo Clinic — GLP-1 Agonists for Type 2 Diabetes and Obesity. Mayo Clinic Proceedings.
This content is produced in accordance with GLP-1 Health's editorial standards and is based on peer-reviewed clinical evidence from the sources cited above. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
Continue Your GLP-1 Research
Who Should NOT Take GLP-1 Medications? Full Contraindications List
Safety & Eligibility · 11 min read
Your First Week on Semaglutide: A Day-by-Day Guide to What's Normal
Getting Started · 10 min read
Tirzepatide Nausea: Why It Happens and the Management Strategies That Actually Work
Side Effects · 10 min read
